686772-17-8
基本信息
2-((3-(2-甲氧基苯基)-4-氧代-3,4,6,7-四氢噻吩并[3,2-D]嘧啶-2-基)硫代)-N-(6-甲基苯并[D]噻唑-2-基)乙酰胺
CS-2394
IWP4
IWP 4
IWP-4 >=95% (HPLC)
Wnt Inhibitor IWP-4
Inhibitor of Wnt Production-4
N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl)thio]-acetamide
Acetamide, N-(6-methyl-2-benzothiazolyl)-2-[[3,4,6,7-tetrahydro-3-(2-methoxyphenyl)-4-oxothieno[3,2-d]pyrimidin-2-yl]thio]-
2-((3-(2-methoxyphenyl)-4-oxo-3,4,6,7-tetrahydrothieno[3,2-d]pyrimidin-2-yl)thio)-N-(6-methylbenzo[d]thiazol-2-yl)acetamide
物理化学性质
| 密度 | 1.51±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | insoluble in H2O; insoluble in EtOH; insoluble in DMSO |
| 酸度系数(pKa) | 9.01±0.70(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
| InChI | 1S/C23H20N4O3S3/c1-13-7-8-14-18(11-13)33-22(24-14)26-19(28)12-32-23-25-15-9-10-31-20(15)21(29)27(23)16-5-3-4-6-17(16)30-2/h3-8,11H,9-10,12H2,1-2H3,(H,24,26,28) |
| InChIKey | RHUJMHOIQBDFQR-UHFFFAOYSA-N |
| SMILES | O=C1C2=C(CCS2)N=C(SCC(NC3=NC(C=CC(C)=C4)=C4S3)=O)N1C5=C(OC)C=CC=C5 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302 |
| 防范说明 | P280-P305+P351+P338 |
| WGK Germany | 3 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Acute Tox. 4 Oral |
CS-2394价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-12879 | IWP-4 | 686772-17-8 | 1 mg | 411元 |
| 2026/09/15 | HY-12879 | CS-2394 IWP-4 | 686772-17-8 | 5mg | 1500元 |
| 2026/09/15 | HY-12879 | CS-2394 IWP-4 | 686772-17-8 | 10mg | 2500元 |
常见问题列表
IC50: 25 nM (Wnt)
IWP-4 is a small molecule Wnt inhibitor with an IC 50 of 25 nM. IWP-4 induces the expression of cardiac markers, including cardiac troponin I (CTNI) and cardiac myosin heavy chain bright cells (MYH hi + ). IWP-4 also results in the appearance of beating foci (0.44±0.10 SEM beats per second), which is absent in all cultures not receiving IWP-4. Further, flow cytometric analysis shows that there are significantly more MYH lo + cells in IWP-4 treated cultures (P<0.0002) compare with untreated cultures at day 16, being 17.0±1.3 SD% and 5.4±1.4 SD%, respectively. Quantification of NKX2-5 protein expression shows that 63% (481/817) of IWP-4 treated cells display nuclear NKX2-5 expression. Mesenchymal precursor cells (MPCs) treated with IWP-4 show no significant changes in the expression of AXIN2 , CTNNB1 and GSK3B as compare to osteogenic medium alone on day 7, but MPCs treated with IWP-4 express elevates levels of DKK1 and GSK3β on day 21. IWP-4 also causes a significant down regulation of SPARC and COL1A1 .